Emerging Trends in Chimeric Antigen Receptor T-Cell Immunotherapy in Young Adults and Pediatric Patients from the Vizient Clinical Database

Chimeric Antigen Receptor T-cell (CAR-T) Immunotherapy was approved by the FDA in 2017 for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL), as well as adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. CAR-T immunotherapy uses a patient's own T cells and modifies them in a laboratory to recognize and kill the patient's cancer. Since the CAR-T modified cells multiply and persist in the patient's bloodstream, they have the potential to protect the patient against recurrence.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 501 Source Type: research